Pulmonary
Partner With Us
Advertisement
Conexiant chevron_right Pulmonary chevron_right GLP 1 Agonists Linked to Fewer COPD Flare Ups
From the Journals

GLP-1 Agonists Linked to Fewer COPD Flares

SGLT-2 inhibitors and GLP-1 receptor agonists were associated with a reduced risk of moderate or severe COPD exacerbations compared with DPP-4 inhibitors in adults with type 2 diabetes.

Conexiant
article Full Article subject Summary summarize Notecard
  1. The study compared the impact of glucose-lowering medications on COPD exacerbations in patients with type 2 diabetes.
  2. SGLT-2 inhibitors and GLP-1 receptor agonists may be preferable to DPP-4 inhibitors for patients with type 2 diabetes and active COPD.
  3. The primary outcome was the first occurrence of a moderate or severe COPD exacerbation, defined as a filled prescription for oral glucocorticoids associated with an outpatient visit or hospitalization.
  4. The study highlighted the need for further clinical studies and trials to corroborate the findings. 
  5. Potential for residual or unmeasured confounding was acknowledged by the authors. 

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.